Kala Subramanian
President bij Profound Therapeutics
Oorsprong van het eerstegraads netwerk van Kala Subramanian
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts.
177
| Private Company | Investment Managers | 177 |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ.
89
| Subsidiary | Pharmaceuticals: Major | 89 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.
49
| Subsidiary | Pharmaceuticals: Major | 49 |
Ichnos Sciences, Inc.
 Ichnos Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ichnos Sciences, Inc. operates as a biotechnology company. It provides curative therapies that extend human life. The company was founded in 2019 and is headquartered in Paramus, NJ.
14
| Private Company | Miscellaneous Commercial Services | 14 |
Profound Therapeutics
 Profound Therapeutics Pharmaceuticals: OtherHealth Technology Profound Therapeutics is a company that is focused on discovering new medicines by expanding the human proteome. The company is based in Cambridge, MA. The company uses their platform, Profoundry, to identify and validate proteins and understand their therapeutic potential. This results in a growing database of novel proteins and their roles in health and disease. The company was founded in 2020 by Avak Kahvejian, who has been the CEO since then.
3
| Holding Company | Pharmaceuticals: Other | 3 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Kala Subramanian via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| Massachusetts Institute of Technology | College/University | Director/Board Member Doctorate Degree Doctorate Degree Corporate Officer/Principal Doctorate Degree Undergraduate Degree Undergraduate Degree Doctorate Degree Graduate Degree Graduate Degree Doctorate Degree | |
| AXCA HEALPAR | Biotechnology | Director/Board Member Founder Director/Board Member Director/Board Member Director of Finance/CFO Founder Chairman Founder Corporate Officer/Principal | |
| RUBIUS THERAPEUTICS | Biotechnology | Chairman Founder Director/Board Member President Chairman Founder Founder Director of Finance/CFO | |
Cellarity Inc.
 Cellarity Inc. BiotechnologyHealth Technology Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA. | Biotechnology | Founder Founder Corporate Officer/Principal Chief Executive Officer Founder Chairman Founder | |
Generate Biomedicines, Inc.
 Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | Biotechnology | Founder Director/Board Member Founder Founder Founder Founder Chief Executive Officer | |
| SERES THERAPEUTICS, INC. | Biotechnology | Founder Founder Founder Director/Board Member Director/Board Member Chairman Chief Operating Officer | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
| EVELO BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member Founder Director/Board Member Founder Chairman Director/Board Member | |
| MODERNA, INC. | Biotechnology | Director/Board Member Director/Board Member Founder Founder Chief Executive Officer Director/Board Member | |
Ring Therapeutics, Inc.
 Ring Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ring Therapeutics, Inc. engages in the development of a gene therapy platform. Its Anellovector platform provides tissue specifities benefitting from the inherent diversity of tropism afforded by the commensal virome. The company was founded in 2000 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Chief Executive Officer Corporate Officer/Principal Chief Executive Officer | |
Repertoire Immune Medicines, Inc.
 Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member Founder Chairman Chief Executive Officer Director/Board Member | |
Cygnal Therapeutics, Inc.
 Cygnal Therapeutics, Inc. BiotechnologyHealth Technology Cygnal Therapeutics, Inc. develops drugs for cancer, immunological diseases and regenerative processes. The company was founded by Noubar Afeyan, Avak Kahvejian and Jordi Mata-Fink in 2017 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Founder Director/Board Member Founder Founder | |
KSQ Therapeutics, Inc.
 KSQ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology KSQ Therapeutics, Inc. develops and deploys precision functional genomics to discover therapies that transform patient lives. The company was founded by Tim Wang and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chairman Chairman Director/Board Member Founder | |
| KALEIDO BIOSCIENCES, INC. | Pharmaceuticals: Major | Chairman Founder Chief Administrative Officer Founder | |
Inzen Therapeutics, Inc.
 Inzen Therapeutics, Inc. BiotechnologyHealth Technology Part of Sonata Therapeutics, Inc., Inzen Therapeutics, Inc. is discovering and developing a novel class of medicines based on thanokine biology. The company is based in Cambridge, MA. Thanokine biology offers the potential for unprecedented approaches to prevent and treat cancer, fibrotic disorders, immune-inflammatory disorders, metabolic disorders, and degenerative diseases. Inzen's thanokine product platform applies advances in mass spectrometry and machine learning, novel probes, unique assays, genetic and chemical biological technologies to characterize thanokine biology at scale and create drug candidates. Inzen Therapeutics harnesses signals of the cellular microenvironment to treat serious diseases. The company was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member President | |
Montai Health, Inc.
 Montai Health, Inc. Packaged SoftwareTechnology Services Montai Health, Inc. is a company that is using its pioneering AI-powered Conecta™ platform to develop Anthromolecule™ medicines that will treat and preempt chronic diseases to improve health outcomes for the 2 billion people worldwide living with these diseases. The company is based in Cambridge, MA. Montai Health is unlocking the potential of Anthromolecule™ chemistry with its pioneering AI-powered Conecta™ platform to develop breakthrough small-molecule medicines that will treat and preempt chronic diseases to improve health outcomes for the two billion people worldwide living with these diseases. The company was founded by Hok Hei Tam, Michael Wong, David Kolesky, Mary Margaret Hastings Georgiadis. Mary Margaret Hastings Georgiadis has been the CEO since incorporation. | Packaged Software | Director/Board Member Founder Founder Chief Operating Officer | |
Ampersand Biomedicines
 Ampersand Biomedicines BiotechnologyHealth Technology Ampersand Biomedicines is an American company that designs programmable medicines that work precisely where needed in the body and nowhere else. The company's computationally powered platform identifies ideal addresses for drug localization and informs the design of and-body™ therapeutics that have the optimal therapeutic effect. The result is smarter biologic medicines that target the site of disease without affecting healthy tissue or cells. Ampersand is enabling potent mechanisms to treat disease by creating and programming therapeutics that are more efficacious, without compromising on safety or tolerability. The company was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering. Jason Gardner has been the CEO of the company since 2023. | Biotechnology | Founder Founder President Chief Executive Officer | |
ModernaTX, Inc.
 ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Founder Chief Executive Officer Director/Board Member | |
Ohana Biosciences, Inc.
 Ohana Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ohana Biosciences, Inc. operates early stage biotechnology firm. The company is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
Indigo Ag, Inc.
 Indigo Ag, Inc. BiotechnologyHealth Technology Indigo Ag, Inc. provides microbial solutions. The company was founded by Noubar Afeyan, David A. Berry, and Geoffrey von Maltzahn in 2013 and is headquartered in Charlestown, MA. | Biotechnology | Founder Founder Director/Board Member Founder | |
| University of California San Diego | College/University | Graduate Degree Corporate Officer/Principal Graduate Degree Doctorate Degree | |
| Harvard Medical School | College/University | Corporate Officer/Principal Doctorate Degree Graduate Degree Doctorate Degree | |
| EXACT SCIENCES CORPORATION | Medical Specialties | Director of Finance/CFO Corporate Secretary Director/Board Member Founder | |
| BG MEDICINE, INC. | Medical Specialties | Chairman Founder Director of Finance/CFO Chairman | |
Valo Health LLC
 Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA. | Packaged Software | Chief Executive Officer Director/Board Member Director/Board Member | |
| Stanford University | College/University | Graduate Degree Graduate Degree Graduate Degree | |
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO President | |
| T2 BIOSYSTEMS, INC. | Medical Specialties | Director/Board Member Director/Board Member Founder | |
| CODIAK BIOSCIENCES | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| University of Oxford | College/University | Doctorate Degree Doctorate Degree Undergraduate Degree | |
Valo Health, Inc.
 Valo Health, Inc. Financial ConglomeratesFinance Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation. | Financial Conglomerates | Founder Director/Board Member Director/Board Member | |
YourBio Health, Inc.
 YourBio Health, Inc. Electronic Equipment/InstrumentsElectronic Technology YourBio Health, Inc. develops health monitoring products. It is developing an array of products based on the company's proprietary TAP? (Touch Activated Phlebotomy) painless blood collection platform. The company was founded by Richard Rox Anderson, Joerg Lahann, Robert S. Langer Jr., Douglas A. Levinson and Samir Mitragotri in 2008 and is headquartered in Medford, MA. | Electronic Equipment/Instruments | Chairman Director/Board Member Director/Board Member | |
| The Trustees of Columbia University in The City of New York | College/University | Corporate Officer/Principal Undergraduate Degree Graduate Degree | |
| SYROS PHARMACEUTICALS, INC. | Biotechnology | Founder Director/Board Member Director/Board Member | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree Corporate Officer/Principal Doctorate Degree | |
| SANA BIOTECHNOLOGY, INC. | Biotechnology | Founder Director/Board Member Director/Board Member | |
Cobalt Biomedicine, Inc.
 Cobalt Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Cobalt Biomedicine, Inc. engages in the development of therapeutic based drugs. The company was founded in 2017 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer | |
| University of Mumbai | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| Dartmouth College | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| McGill University | College/University | Undergraduate Degree Doctorate Degree Graduate Degree | |
Empress Therapeutics, Inc.
 Empress Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Empress Therapeutics, Inc. is a company that was founded by Flagship Pioneering in 2020. The company is based in Cambridge, MA. Empress Therapeutics generates medicines quickly by using the chemistry inside the human body. The company uses the Empress Chemilogics™ platform to create first- or oral medicines for a broad range of diseases quickly, predictably, and cost-effectively. The platform uses novel insights that connect the lines of code in DNA with drug-like chemistry made in the human body. Jason Park is the founder of the company and has been the CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer |
Statistieken
Internationaal
| Verenigde Staten | 48 |
| Verenigd Koninkrijk | 2 |
| India | 2 |
| Canada | 2 |
Sectoraal
| Health Technology | 29 |
| Consumer Services | 11 |
| Commercial Services | 7 |
| Finance | 3 |
| Technology Services | 3 |
Operationeel
| Director/Board Member | 370 |
| Corporate Officer/Principal | 124 |
| Founder | 111 |
| Independent Dir/Board Member | 90 |
| Private Equity Investor | 74 |
Sterkste connecties
| Insiders | |
|---|---|
| Noubar Afeyan | 76 |
| Douglas Cole | 44 |
| Harry Wilcox | 33 |
| David Berry | 31 |
| Ed Kania | 31 |
| Michael Rosenblatt | 31 |
| David Epstein | 29 |
| Charles Homcy | 28 |
| John Mendlein | 27 |
| Theo Melas-Kyriazi | 26 |
| Stéphane Bancel | 23 |
| Lawrence Olanoff | 22 |
| James Gilbert | 20 |
| Kevin Starr | 19 |
| Glenn Mario Saldanha | 17 |
- Beurs
- Insiders
- Kala Subramanian
- Bedrijfsconnecties
